Last updated: May 23, 2026
Sirolimus supply chains split into (1) sirolimus active pharmaceutical ingredient (API) and (2) finished-dose products across tablets and oral solutions used for transplant immunosuppression and some oncology indications.
Which companies supply sirolimus API (active pharmaceutical ingredient)?
Sirolimus API is typically sourced through specialized manufacturers with high-containment fermentation/chemistry capability and GMP track record for macrolide immunosuppressants.
Common SIROLIMUS API manufacturing regions and typical supplier profiles
- Specialty generics and complex APIs in India, China, and parts of Europe supply commercial API lots under DMF or alternative dossier pathways.
- Originator and branded-license supply chains often rely on contracted API makers plus controlled drug-product plants for finished dosage.
How to map API suppliers without relying on incomplete “lists”
For high-stakes sourcing, the reliable public map is built from:
- FDA DMF holders and cross-references tied to sirolimus dosage applications
- Orange Book / FDA drug labels that name manufacturers and packagers for marketed products
- Contract manufacturing disclosures in regulatory filings and label “manufactured for” statements
(Exact API supplier identities by DMF holder require Orange Book and FDA database crosswalk for each specific NDA/ANDA and strength; those elements are product-specific.)
What companies supply branded sirolimus finished products (tablets) such as Rapamune?
Sirolimus marketed in the US under branded and authorized generic product labels has fixed manufacturer and packager lines on the prescribing information.
Brand-name sirolimus (Rapamune) supply chain elements
A branded product label typically lists:
- Manufacturing site(s) for the finished dosage form (tablet)
- Packager/distributor, sometimes with multiple labeled sites over time
- Testing and release sites for specific strengths
Where supplier identity shows up in practice
- US FDA label “Manufactured for” fields and NDC labeler codes
- Sponsor/manufacturer blocks in FDA approval package records for each strength
Because supplier identity can shift by site over years, any sourcing plan should lock to the current label NDC for the target strength and submission.
Who supplies sirolimus oral solution or liquid formulations?
Oral solution and concentrated liquid formats have narrower supplier pools because the formulation needs:
- Solubilization and stability control for a highly lipophilic macrolide
- Controlled manufacturing for viscosity, extraction, and filtration steps
- Bottle closure and transport validation for GMP
Supplier coverage is usually concentrated in plants that already run complex macrocyclic lactone oral formulations.
What about sirolimus “authorized generics” and generic manufacturers?
Generic sirolimus tablets enter through ANDA and rely on:
- API sourcing that meets the generic method of manufacture and specifications
- Drug product manufacturing in plants with validated dissolution profiles and controlled particle-size strategy for BCS-like behavior
Generic supplier mapping method that supports procurement
- Identify each ANDA’s drug product manufacturer from the FDA label for each NDC/strength
- Link to the corresponding API DMF reference when publicly visible
- Treat “company name on label” as the commercial manufacturer, not necessarily the API maker
How does the supplier chain differ between transplant use and oncology uses?
Sirolimus is used for:
- Transplant immunosuppression (primary driver for tablet/oral liquid supply)
- Oncology (where used as an mTOR pathway inhibitor; product form and regulatory authorizations vary by jurisdiction)
Supply chain differences stem from:
- Formulation and dosage form requirements tied to the regulatory approval
- Quality system requirements tied to specific NDA/ANDA dossiers
- Distributor channels and cold-chain expectations only if the specific product requires it (many sirolimus presentations are room-temperature handled)
What procurement risks exist when sourcing sirolimus?
API supply continuity and substitution constraints
Sirolimus API is a complex molecule with strict specifications. Switching API suppliers can trigger:
- Regulatory filing updates (if the DMF reference changes)
- New stability and bioequivalence support for drug product, depending on the submission type
- Increased inspection and audit focus on process controls and residuals
Regulatory and quality constraints
High-risk points for macrolides include:
- Impurity control (process-related and degradation impurities)
- Solvent residuals and polymorph/particle-size control for consistent dissolution
- Consistency of strength, homogeneity, and content uniformity for tablets
What is the supplier due-diligence checklist for sirolimus?
Procurement teams typically operationalize these checks:
- GMP certificate coverage for API and drug product sites
- Published inspection history for the relevant facilities
- DMF status for API and linkage to the finished dosage dossier
- Specification pack: impurities, residual solvents, water content, particle-size strategy, and shelf-life assumptions
- Batch release data (COA trend analysis) tied to historical lots, not single-lot snapshots
- Change-control record for the specific plant used to support continuity of supply
How many supplier tiers typically exist for sirolimus?
A functional supply chain for sirolimus generally includes:
- API manufacturer (often DMF-linked)
- Finished-dose manufacturer (tablet/oral solution)
- Packager/distributor (labeler and market logistics)
- Optionally, raw-material intermediates upstream of API synthesis
Commercial continuity is usually bottlenecked at the API tier and the specialized drug product formulation tier.
Key Takeaways
- Sirolimus supply is tiered: API makers and finished-dose manufacturers differ, and supplier identity changes over time by NDC strength and label site.
- The most procurement-reliable supplier mapping comes from FDA label manufacturing blocks tied to specific NDCs plus FDA DMF reference linkage for the API.
- Due diligence for sirolimus centers on impurity control, particle-size and dissolution consistency for tablets, solubilization stability for oral liquids, and continuity of supply at the API tier.
- For sourcing decisions, lock to the current marketed NDC/strength and verify the exact labeled manufacturing site(s) and the referenced API dossier.
FAQs
1) Who manufactures Rapamune (sirolimus) tablets in the US?
The manufacturer and packager are identified on the Rapamune FDA label for each strength and NDC, and can change by site across years.
2) What is the difference between sirolimus API suppliers and sirolimus drug-product manufacturers?
API suppliers produce the active ingredient under DMF or comparable regulatory dossiers; drug-product manufacturers formulate, blend, compress/fill, and release the finished tablets or oral solutions.
3) Can generic sirolimus tablets use a different API supplier than the originator?
Yes in principle, but the generic dossier links to API quality and controls, and changing the API reference can require regulatory and stability/quality updates depending on submission strategy.
4) What quality attributes matter most for sirolimus tablet dissolution and bioavailability?
Particle-size distribution, content uniformity, impurity profile, residual solvents, and the dissolution method aligned to the dossier.
5) How do I identify the current sirolimus finished-dose manufacturing site for a specific NDC?
Use the latest FDA label text for that NDC and strength to read the “manufactured for” and site information.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA Drug Labels (Prescribing Information) for sirolimus products. U.S. Food and Drug Administration.
- FDA Electronic Orange Book and Drug Approvals data (NDA/ANDA label and manufacturer fields). U.S. Food and Drug Administration.
